Orbit azine-fumarate compounds are provided having the following formula:
Different crystal forms of orbit azine-fumarate, an orbit azine-fumarate hydrate and a crystal form thereof, and an amorphous form of orbit azine-fumarate are prepared by adjusting the ratio of orbit azine and fumaric acid and using different crystallization methods. The invention makes it possible to provide an orbit azine-fumarate which has a higher pharmaceutical effect, is easier to prepare, and has improved storage stability.
本发明提供了具有以下公式的轨道嗪-
富马酸盐化合物:通过调整轨道嗪和
富马酸的比例并使用不同的结晶方法,制备了轨道嗪-
富马酸盐的不同晶体形式、轨道嗪-
富马酸盐的
水合物及其晶体形式以及轨道嗪-
富马酸盐的非晶形式。本发明使得提供具有更高药效、更易制备和改善储存稳定性的轨道嗪-
富马酸盐成为可能。